A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

Active:	No
Cancer Type:	Unknown Primary Uterine Cancer	NCT ID:	NCT03981796
Trial Phases:	Phase III	Protocol IDs:	213361 (primary) 4010-03-001 NCI-2019-04891 GOG-3031 ENGOT-EN6
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	Tesaro Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT03981796

Summary

This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus
carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel
followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus
carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus
carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced
(Stage III or IV) endometrial cancer.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.